Amgen 2001 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

We’re entering a more
demanding, more
competitive era in thera-
peutic development.
Effective products remain
the essential ingredient
in our business, to be
sure. But we must also
engage the market on its
own terms, addressing
cost and relative efficacy
in addition to long-term
patient outcomes.
George Morrow Executive Vice President, Worldwide Sales and Marketing
Markets Worth Developing
“What does brand-building have to do with improving
patients’ lives? Quite a lot, actually. Developing commercially
successful therapeutics is as much about trust and
collaboration as it is about good science.”
Aranesp
™
is a product with
blockbuster potential. Its
less-frequent dosing offers
significant advantages. And
its long-term market potential
is huge–anemia remains a
frequently undiagnosed,
under-treated condition. Our
challenge is to ensure that
people understand and act on
those facts.
There is a good deal of
uncertainty inherent in
our business. The more
closely we collaborate
and communicate within
Amgen throughout the
development process,
the stronger the platform
from which we will
launch successful new
products in important
new markets.
12